Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 9:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 107,141 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Study Clear all
Completed No phase listed Observational Accepts healthy volunteers

A Novel Assay for Predicting Surgical Outcomes in Pelvic Organ Prolapse

NCT03534830
View directory record Official record
Conditions
Prolapse Genital
Interventions
MRI
Diagnostic Test
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older · Female only
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Oct 24, 2026, 9:17 PM EDT
Completed Phase 2 Interventional

Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis

NCT01384630
View directory record Official record
Conditions
Psoriasis
Interventions
RA-18C3
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Owensboro, Kentucky • Ann Arbor, Michigan • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 24, 2026, 9:17 PM EDT
Completed Phase 2 Interventional

Safety of Pioglitazone for Hematoma Resolution In Intracerebral Hemorrhage

NCT00827892
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
Pioglitazone, Placebo Control
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 80 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2015 · Synced Oct 24, 2026, 9:17 PM EDT
Completed Not applicable Interventional Results available

Feasibility Study Using Zone-MPC Controller, HMS and Technosphere® Insulin Inhalation System From MannnKind Corp

NCT01874392
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Investigational inhaled insulin (Technosphere), Artificial Pancreas (AP) device (APS©)
Drug · Device
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
21 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Oct 24, 2026, 9:17 PM EDT
Completed Phase 2 Interventional

Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug

NCT00988936
View directory record Official record
Conditions
Metastatic Breast Cancer, Metastatic Colon/Rectum Cancer, Non-squamous Non-small Cell Lung Cancer
Interventions
[F-18]RGD-K5
Drug
Lead sponsor
Siemens Molecular Imaging
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
8
States / cities
Irvine, California • Los Angeles, California • Newark, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2012 · Synced Oct 24, 2026, 9:17 PM EDT
Not listed Not applicable Interventional

Study of Treatment Effects of Combination Therapy of Lucentis Plus Reduced Fluence PDT With Visudyne in Patients With Exudative AMD

NCT00455871
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
reduced fluence photodynamic therapy with Visudyne, Lucentis
Drug
Lead sponsor
Barnes Retina Institute
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 9, 2008 · Synced Oct 24, 2026, 9:17 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

NCT02339571
View directory record Official record
Conditions
Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions
Biospecimen Collection, Computed Tomography, Echocardiography Test, Ipilimumab, Magnetic Resonance Elastography, Multigated Acquisition Scan, Nivolumab, Sargramostim
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2033
U.S. locations
763
States / cities
Birmingham, Alabama • Kingman, Arizona • Little Rock, Arkansas + 494 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 24, 2026, 9:17 PM EDT
Recruiting Not applicable Interventional

Development and Feasibility of CTraC-FIT

NCT07132944
View directory record Official record
Conditions
Functional Impairment, Functional Performance
Interventions
CTraC-FIT, Enhanced Usual Care
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
65 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 24, 2026, 9:17 PM EDT
Completed Phase 1 Interventional Results available

Three Way Crossover Closed Loop Study With Xeris Glucagon

NCT03424044
View directory record Official record
Conditions
Type1diabetes
Interventions
Artificial Pancreas Controller in Dual Hormone Mode, Artificial Pancreas Controller in Single Hormone Mode, Artificial Pancreas Controller in Predictive Low Glucose Suspend Mode, XeriSol glucagon
Device · Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 50 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Oct 24, 2026, 9:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Cognitive Effects of Fesoterodine in Elderly Subjects

NCT01161472
View directory record Official record
Conditions
Healthy
Interventions
4mg fesoterodine, 8mg fesoterodine, alprazolam 1mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
65 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2012 · Synced Oct 24, 2026, 9:17 PM EDT
Recruiting Not applicable Interventional

Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors

NCT07390045
View directory record Official record
Conditions
Cancer
Interventions
EXCAP, MAAT, ECO
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
65 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 24, 2026, 9:17 PM EDT
Not listed No phase listed Observational

Pediatric Acute Gastrointestinal Bleeding Registry

NCT03090945
View directory record Official record
Conditions
Upper Gastrointestinal Bleeding, Gastro Intestinal Bleeding
Interventions
This is an obsevational cohort study
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 21 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
3
States / cities
Chicago, Illinois • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 24, 2026, 9:17 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Botulinum Toxin Type A (Botox) for the Treatment of Cervical Dystonia and Upper Thoracic Muscular Pain

NCT00178945
View directory record Official record
Conditions
Refractory Cervicothoracic Myofascial Pain Syndrome (CMPS), Cervical Dystonia
Interventions
Botulinum Toxin Type A
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Oct 24, 2026, 9:17 PM EDT
Completed Phase 2 Interventional Results available

Ricolinostat in Patients With Painful Diabetic Peripheral Neuropathy

NCT03176472
View directory record Official record
Conditions
Painful Diabetic Peripheral Neuropathy
Interventions
ricolinostat, Placebo
Drug
Lead sponsor
Regenacy Pharmaceuticals LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
35
States / cities
Anniston, Alabama • Phoenix, Arizona • Huntington Beach, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 24, 2026, 9:17 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of an Anticholinergic Agent for Treatment of Primary Axillary Hyperhidrosis

NCT02193139
View directory record Official record
Conditions
Hyperhidrosis
Interventions
WL8713, 6 mg, WL8713, 12 mg, WL8713, 18 mg, WL8713, 24 mg, Placebo
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2015 · Synced Oct 24, 2026, 9:17 PM EDT
Terminated Phase 2 Interventional Results available

MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer

NCT01319539
View directory record Official record
Conditions
Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, HER2/Neu Positive, Progesterone Receptor Negative, Progesterone Receptor Positive, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Akt Inhibitor MK2206, Therapeutic Conventional Surgery, Pharmacological Study, Laboratory Biomarker Analysis
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Oct 24, 2026, 9:17 PM EDT
Terminated Phase 2 Interventional Results available

Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer

NCT02654639
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
TAS-102, Bevacizumab
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 24, 2026, 9:17 PM EDT
Completed Not applicable Interventional

Training Swallowing Initiation During Expiration

NCT05278039
View directory record Official record
Conditions
Head and Neck Cancer, Dysphagia, Oropharyngeal Dysphagia, Oropharynx Squamous Cell Carcinoma
Interventions
Respiratory-Swallow Phase Training, Swallow Practice
Behavioral · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 24, 2026, 9:17 PM EDT
Not yet recruiting Not applicable Interventional

Altius Peripheral Nerve Stimulation in Amputees After TMR/RPNI

NCT07571239
View directory record Official record
Conditions
Amputation; Lower Extremity, Pain, Persistent Postsurgical
Interventions
Surgical Implantation
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 24, 2026, 9:17 PM EDT
Recruiting Not applicable Interventional

PET/CT Imaging to Evaluate Cardiac Radiation Damage in Patients With Lung or Esophageal Cancer, EUCLID Trial

NCT05775939
View directory record Official record
Conditions
Lung Carcinoma, Esophageal Carcinoma
Interventions
Fludeoxyglucose F-18, Positron Emission Tomography, Computed Tomography, Questionnaire Administration
Other · Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 24, 2026, 9:17 PM EDT
Terminated Phase 1 Interventional

A Study of HFB301001 in Adult Patients With Advanced Solid Tumors

NCT05229601
View directory record Official record
Conditions
Soft Tissue Sarcoma, Renal Cell Carcinoma, Uterine Carcinosarcoma, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma
Interventions
HFB301001
Drug
Lead sponsor
HiFiBiO Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
7
States / cities
Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 24, 2026, 9:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Patient Satisfaction With Contoura Vision Topography-Guided LASIK

NCT04903301
View directory record Official record
Conditions
Myopia, Astigmatism
Interventions
Contoura Vision LASIK
Procedure
Lead sponsor
Rush Eye Associates
Other
Eligibility
21 Years to 35 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Amarillo, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 24, 2026, 9:17 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.

NCT05035212
View directory record Official record
Conditions
Lower Respiratory Tract Illness
Interventions
RSVpreF, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
60 Years and older
Enrollment
38,861 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
176
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 119 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 24, 2026, 9:17 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study

NCT04550481
View directory record Official record
Conditions
Hepatocellular Carcinoma, Nonalcoholic Steatohepatitis
Interventions
Biospecimen Collection, Lisinopril, Liver Ultrasonographic Elastography, Magnetic Resonance Elastography, Magnetic Resonance Imaging, Proton Density Fat Fraction, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
Los Angeles, California • Rochester, Minnesota • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 24, 2026, 9:17 PM EDT